Core Viewpoint - Compass Therapeutics is a monoclonal antibody discovery and development company focused on oncology, with significant advancements in its drug pipeline, including positive efficacy signals for its drugs in clinical trials [2][3]. Group 1: Company Overview - Compass Therapeutics is based in Boston, Massachusetts, and specializes in monoclonal antibody development for cancer treatment [2]. - The company has three drugs currently in clinical trials and plans to introduce a fourth drug this quarter [2]. Group 2: Pipeline and Clinical Trials - The most advanced program is Tovecimig, a DLL4 VEGF-A bispecific antibody, which is a next-generation angiogenesis inhibitor [3]. - Tovecimig recently achieved the primary endpoint in a randomized study involving patients with advanced biliary tract cancer [3]. - Data from a Phase II study of Tovecimig in patients with very advanced colorectal cancer was presented at ASCO GI, demonstrating unequivocal monotherapy efficacy [4].